Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: A Southwest Oncology Group study.

被引：0
|
作者：
Whitehead, R. P.
Mccoy, S.
Wollner, I. S.
Wong, L.
Harker, W. G.
Hoff, P. M.
Gold, P. J.
Billingsley, K. G.
Blanke, C. D.
机构：
[1] Univ Texas, Med Branch, Galveston, TX 77555 USA
[2] SW Oncol Grp, Ctr Stat, Seattle, WA USA
[3] Henry Ford Hosp, Detroit, MI 48202 USA
[4] White CCOP, Temple, TX USA
[5] Utah Canc Specialists, Salt Lake City, UT USA
[6] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Swedish Canc Inst, Seattle, WA USA
[8] Oregon Hlth Sci Univ, Inst Canc, Portland, OR 97201 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3598
引用
收藏
页码：170S / 170S
页数：1
相关论文
共 50 条
  • [31] Tucatinib in patients with locally advanced or metastatic HER2-positive breast cancer who received at least two prior anti-HER2 treatment regimens: Study design of the non-interventional study TRACE in Germany and Austria
    Nusch, Arnd
    Angerer, Moritz
    Welslau, Manfred
    Uleer, Christoph
    Radosa, Julia
    Wrobel, Denise
    Noeding, Stefanie
    Apel, Klaus
    Terhaag, Juergen
    Tamm, Ingo
    Bauer, Lelia
    Balic, Marija
    Egle, Daniel
    Harbeck, Nadia
    Mueller, Volkmar
    Schumacher-Wulf, Eva
    De Buhr, Rebecca
    Glasstetter, Martin
    Hanselmann, Johanna
    Hogrefe, Cathrin
    Marschner, Norbert
    Gratze, Katja
    Bartsch, Rupert
    Welt, Anja
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 28 - 28
  • [32] A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501
    Schiller, J. H.
    Lee, J. W.
    Hanna, N. H.
    Traynor, A. M.
    Carbone, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] A phase I-II trial of Ispinesib, a kinesin spindle protein inhibitor, dosed every two weeks in patients with locally advanced or metastatic breast cancer previously untreated with chemotherapy for metastatic disease or recurrence.
    Gomez, H.
    Castaneda, C.
    Philco, M.
    Pimentel, P.
    Falcon, S.
    Escandon, R.
    Saikali, K.
    Conlan, M.
    Seroogy, J.
    Wolff, A.
    CANCER RESEARCH, 2009, 69 (02) : 199S - 200S
  • [34] Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group Trial E2196
    Sparano, JA
    Bernardo, P
    Stephenson, P
    Gradishar, WJ
    Ingle, JN
    Zacker, S
    Davidson, NE
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (23) : 4683 - 4690
  • [35] A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen
    Paul Ruff
    D. A. Vorobiof
    J. P. Jordaan
    G. S. Demetriou
    S. D. Moodley
    A. L. Nosworthy
    I. D. Werner
    J. Raats
    L. J. Burgess
    Cancer Chemotherapy and Pharmacology, 2009, 64
  • [36] A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen
    Ruff, Paul
    Vorobiof, D. A.
    Jordaan, J. P.
    Demetriou, G. S.
    Moodley, S. D.
    Nosworthy, A. L.
    Werner, I. D.
    Raats, J.
    Burgess, L. J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (04) : 763 - 768
  • [37] Phase II trial of cabazitaxel in patients with advanced or metastatic transitional cell carcinoma of the urothelial tract who have progressed within less than 12 months after cisplatin-based chemotherapy: A Spanish Oncology Genitourinary Group (SOGUG) study
    Arranz Arija, Jose Angel
    Climent Duran, Miguel Angel
    Font Pous, Albert
    Garcia Alonso, Mirta
    Gallardo Diaz, Enrique
    Garcia del Muro, Xavier
    Gonzalez del Alba, Aranzazu
    Lainez Milagro, Nuria
    Lazaro Quintela, Martin
    Lopez-Brea, Marta F.
    Lopez Criado, M. Pilar
    Luque Caro, Raquel
    Martin Lorente, Cristina
    Mendez Vidal, Maria Jose
    Pinto Marin, Alvaro
    Saez, M. I.
    Santander Lobera, Carmen
    Vazquez Estevez, Sergio
    Virizuela Echaburu, Juan
    Duran, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] ISEL: a Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens
    Thatcher, N
    Chang, A
    Parikh, P
    Pemberton, K
    Archer, V
    LUNG CANCER, 2005, 49 : S4 - S4
  • [39] A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy
    Ji, Dongmei
    Shen, Weina
    Zhang, Jian
    Cao, Junning
    Li, Wenhua
    Lam, Lisa H.
    Wu, Fan
    Wang, Bei
    Li, Zao
    Sun, Guofang
    Hu, Xichun
    Chen, Shang-Chiung
    MEDICINE, 2020, 99 (44) : E22886
  • [40] A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
    Park, Yeon Hee
    Lee, Kyung-Hun
    Sohn, Joo Hyuk
    Lee, Keun Seok
    Jung, Kyung Hae
    Kim, Jee-Hyun
    Lee, Ki Hyeong
    Ahn, Jin Seok
    Kim, Tae-Yong
    Kim, Gun Min
    Park, In Hae
    Kim, Sung-Bae
    Kim, Se Hyun
    Han, Hye Sook
    Im, Young-Hyuck
    Ahn, Jin-Hee
    Kim, Jung-Yong
    Kang, Jahoon
    Im, Seock-Ah
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (12) : 3240 - 3247
12345